Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer

MLA

Hitoshi Araki, et al. “Therapeutic Outcomes of Neoadjuvant and Concurrent Androgen-Deprivation Therapy and Intensity-Modulated Radiation Therapy with Gold Marker Implantation for Intermediate-Risk and High-Risk Prostate Cancer.” International Journal of Urology, vol. 22, Feb. 2015, pp. 477–82. EBSCOhost, https://doi.org/10.1111/iju.12707.

APA

Hitoshi Araki, Toshiyuki Imagumbai, Atsushi Komaru, Kazuo Hatano, Takeshi Ueda, Satoshi Fukasawa, Takeshi Namekawa, Ryusuke Hara, Masayuki Kobayashi, & Tomohiko Ichikawa. (2015). Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer. International Journal of Urology, 22, 477–482. https://doi.org/10.1111/iju.12707

Chicago

Hitoshi Araki, Toshiyuki Imagumbai, Atsushi Komaru, Kazuo Hatano, Takeshi Ueda, Satoshi Fukasawa, Takeshi Namekawa, Ryusuke Hara, Masayuki Kobayashi, and Tomohiko Ichikawa. 2015. “Therapeutic Outcomes of Neoadjuvant and Concurrent Androgen-Deprivation Therapy and Intensity-Modulated Radiation Therapy with Gold Marker Implantation for Intermediate-Risk and High-Risk Prostate Cancer.” International Journal of Urology 22 (February): 477–82. doi:10.1111/iju.12707.